Among other accomplishments during his tenure, Mann's companies provided the electric power for over 100 spacecraft and constructed one of the lunar experiments.

At the time of his death, Mann was involved in several companies, including: In June 2014, the US Food and Drug Administration approved MannKind Corporation's application for a unique inhalable insulin (Afrezza) for the treatment of diabetes.

[6] Mann was chairman of the board of MannKind Corporation, a biomedical company, where he also served as chief executive officer until January 12, 2015.

AMI was founded in 1998 when Alfred Mann made his first $100 million gift to USC, a major private research university in Los Angeles.

The Alfred Mann Foundation for Biomedical Engineering is charged with selecting, establishing and overseeing the institutes, similar to AMI at USC and at other research universities.

It aims to work with scientists and research organizations to find bionic solutions for people suffering from debilitating medical impairments.

[12] However, AMI Purdue was closed and the unspent portion of the $100 million endowment from the MANN Foundation was rescinded in early 2012.